Merck has a potential blockbuster in Anacetrapib experimental cholesterol-lowering LDL "bad" cholesterol drug, HDL or "good" cholesterol increases even as you.
The drug potentially turnover of more than $1 billion per year could have wrote John Boris, analyst at Citigroup in a note to investors on Wednesday.
But don't keep your Atem.Kardiologen, patients and investors will have to wait until at least until 2015 to find out whether Anacetrapib protects heart, by reduced heart attacks and other heart circulation problems, said Merck.
Anacetrapib works by inhibiting an enzyme called CETP that is involved in the conversion of particles of the good cholesterol in bad cholesterol.
According to a new study of 1623 patients who already Statins your cholesterol tax there were, patients in a group under Anacetrapib saw also a 39.8 percent reduction in bad cholesterol in the placebo group.More striking, Anacetrapib according to the study, published Wednesday in the New England Journal of medicine promising said also scope for increased 138.1 percent in which good Cholesterin.Das is in theory, doctors because epidemiological studies - the kind that consider the illness in a population - have an association between high good cholesterol and lower risk for heart problems reported Group had.
But the real impact of Anacetrapib on heart health from is not known one will lead to researchers studied much larger study, whether the drug, coronary can reduce the risk of heart attacks, deaths and other heart problems, said Dr. Luciano Rossetti, head of global scientific strategy at Merck research laboratories.
"The results"are promising and reassuring, but inconclusive,"said Dr. Rossetti in a telephone interview.""This is why we are forward with 30,000 patients in a very large results study."
Merck is £ 96 million expenditure - about 150 million US dollars - the larger study that sponsor is by researchers at the University of Oxford coordinated and close before 2015, he said.
Merck needs such results data before it approval of food and Drug Administration on the market said the drug cardiologists searches because a similar experimental drug Pfizer turned out to be problematic.
In 2004, an early study of people, the Pfizer drug, a CETP inhibitor Torcetrapib called, reported that it could improve good cholesterol and bad cholesterol reduction.
But later a large results study showed that the drug increases the risk of death from heart attacks by 25 percent and 59 percent.After spending more than develop $800 million, the drug, Pfizer ended development in 2006.
Dr. Rossetti said Merck researchers intensively the Pfizer drug to ensure that there was no similar Probleme.Torcetrapib, such as levels of aldosterone, can increase a hormone, can increase blood pressure, he said.
But the new study reported no significant differences in change of blood pressure or aldosterone levels between Anacetrapib groups and placebo.
The study also reported that there were 16 cardiac events - including four deaths from heart cycle causes-Anacetrapib group compared with 21 major heart problems, including a cardiovascular-related death, in the Placebogruppe.Aber the difference was not statistically significant, Studie.Die Anacetrapib group said fewer operations in so-called Revascularizations underwent open an artery.
Dr. Howard Weintraub, a cardiologist who the Clinical Director of the Center for the prevention of cardiovascular disease at NYU Langone is Medical Center, said anacetrapib's ability to raise good cholesterol beeindruckend.Aber was he said cardiologists still didn't know whether artificially increasing good cholesterol automatically had a protective effect on the heart level.
Good cholesterol, said Dr. Weintraub, works like a garbage truck with to the Recycle Bin, the bad cholesterol password.but quality, not only the amount that may be important said the risk of heart disease, the good cholesterol to reduce it.
But artificially increase that good cholesterol with a drug may not have the same effect on the heart as naturally increase only the larger results study about Anacetrapib the heart health issue can answer, he said.
0 comments:
Post a Comment